Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1 (NK-1) receptor antagonist HRS5580 has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the prevention of postoperative nausea and vomiting (PONV) in combination with palonosetron hydrochloride injection. HRS5580 represents a potential first-in-class long-acting NK-1 antagonist formulation, addressing a significant gap in the current antiemetic market landscape.

Regulatory Milestone

Drug Profile & Competitive Differentiation

• Mechanism of Action: Selective NK-1 receptor antagonist that blocks substance P binding with high affinity, providing potent antiemetic effects through central nervous system pathway modulation
• Key Advantages:
• High solubility enabling favorable formulation characteristics
• Long-acting efficacy – potentially first long-acting NK-1 antagonist in development
• Favorable safety profile based on preclinical and early clinical data
• Market Gap: Current approved NK-1 antagonists like Heron Therapeutics’ aprepitant injectable emulsion (APONVIE) are short-acting formulations, creating opportunity for extended-duration therapy
• Combination Strategy: Paired with palonosetron (5-HT3 antagonist) to provide comprehensive multi-pathway PONV prevention covering both acute and delayed phases

Market Opportunity & Clinical Need

Postoperative nausea and vomiting affects 30-80% of surgical patients depending on risk factors, representing one of the most common and distressing postoperative complications. The global PONV therapeutics market is valued at approximately $2.5 billion annually, with combination therapies increasingly becoming standard of care for moderate-to-high risk patients.

Current treatment limitations include:

• Short duration of action requiring multiple doses or continuous infusion
• Suboptimal efficacy in high-risk patient populations
• Formulation challenges limiting administration flexibility
• Incomplete coverage of both acute (0-24 hours) and delayed (24-120 hours) PONV phases

HRS5580’s long-acting profile could enable single-dose administration with sustained protection throughout the critical postoperative period, potentially improving patient outcomes and reducing healthcare resource utilization.

Strategic Implications

• For Hengrui: Expands oncology-focused portfolio into perioperative care market, diversifying revenue streams beyond cancer therapeutics
• Competitive Positioning: Potential first-mover advantage in long-acting NK-1 antagonist segment with significant differentiation from existing short-acting competitors
• Global Potential: Success in Chinese market could support international regulatory filings and partnership opportunities with global pharmaceutical companies
• Commercial Strategy: Leverage Hengrui’s established hospital sales force and perioperative care relationships for rapid market penetration

Next Steps

• Clinical Trial Design: Phase II/III study evaluating efficacy and safety of HRS5580-palonosetron combination versus standard of care
• Primary Endpoints: Complete response rate (no emesis, no rescue medication) during 0-120 hour postoperative period
• Regulatory Pathway: Potential for accelerated approval based on unmet need and differentiated profile
• Manufacturing Scale-up: Prepare commercial-scale production capabilities pending successful clinical outcomes

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive developments, and market acceptance.-Fineline Info & Tech